Teriparatide

Abstract

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.

Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800–322–4349. The May 2003 monograph topics are enfuvirtide, oxybutynin transdermal, gemifloxacin, efalizumab, and hyaluronidase ovine. The DUE is on enfurvirtide.

Get full access to this article

View all access options for this article.

References

Forteo [package literature]. Eli Lilly and Company; November 2002.

Neer

R.M.

Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

N Engl J Med. 2001; 344: 1434–41.

Lilly Research Laboratories. LY333334 (Teriparatide injection) briefing document. Teriparatide injection NDA 21–318. June 15, 2001.

Schneider

B.S.

Center for Drug Evaluation and Research.

Food and Drug Administration. Executive summary for advisory committee. NDA 21–318 July 27, 2001.

Lindsay

The reduced risk of new vertebral fracture persists for up to 18 months following treatment of postmenopausal osteoporosis with recombinant human parathyroid hormone (1–34) [abstract].

Arth Rheum. 2001; 44(suppl 9): S379.

Rittmaster

R.S.

Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.

J Clin Endocrinol Metab. 2000; 85: 2129–34.

Body

J.J.

A randomized doubleblind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis.

J Clin Endocrinol Metab. 2002; 87: 4528–35.

Lindsay

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on estrogen with osteoporosis.

Lancet. 1997; 350: 550–5.

Cosman

Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.

J Bone Miner Res. 2001; 16: 925–31.

10.

Finkelstein

J.S.

Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1–34): A randomized controlled trial.

JAMA. 1998; 220: 1067–73.

11.

Finkelstein

J.S.

Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency.

N Engl J Med. 1994; 331: 1618–23.

12.

Finkelstein

J.S.

Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis.

J Clin Endocrinol Metab. 1999; 84: 1214–9.

13.

Lane

N.E.

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: Results of a randomized controlled clinical trial.

J Clin Invest. 1998; 102: 1627–33.

14.

Lane

N.E.

Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial.

J Bone Miner Res. 2000; 15: 944–51.

15.

Kurland

E.S.

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers.

J Clin Endocrinol Metab. 2000; 85: 3069–76.

16.

Winer

K.K.

A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1–34 in treatment of hypoparathyroidism.

J Clin Endocrinol Metab. 1998; 83: 3480–6.

17.

Center for Drug Evaluation and Research. Medical safety review. NDA 21–318. Food and Drug Administration. www.fda.gov. Accessed July 27, 2001.

18.

Benson

C.T.

, Voelker

Randomized, single-blind, crossover, interaction study of teriparatide and digoxin pharmacodynamics in healthy volunteers [abstract].

J Clin Pharmacol. 2002; 42: 1052.